What is Mounjaro?
Mounjaro is a new drug from Eli Lilly with the active ingredient Tirzepatid. It is the first approved dual agonist that simulates two intestinal hormones simultaneously: GLP-1 and GIP.
What makes Mounjaro special: Unlike Ozempic or Wegovy, which only imitate GLP-1, Tirzepatid acts on two hormone receptors. This leads to a stronger effect on weight and blood sugar.
Current approval:
- Approved for type 2 diabetes in the EU
- Approved for weight reduction (under the name Zepbound) in the USA
- EU approval for obesity is expected
Study results: In the SURMOUNT study, participants lost an average of 20-22% of their body weight – more than any other approved drug.
Active Ingredients & Mechanism of Action
Active ingredient: Tirzepatid
Tirzepatid is a dual agonist that imitates two incense hormones:
GLP-1 action:
- Enhanced saturation
- Slowed gastric emptying
- Improved insulin secretion
GIP action:
- Additional appetite suppression
- Improved fat metabolism
- Synergistic effect with GLP 1
**The combination leads to:* *
- Stronger appetite reduction as pure GLP-1 agonists
- Higher weight loss
- Better blood sugar control
- Improved fat metabolism
SURMOUNT study results:
- 15 mg: Average 22.5% weight loss
- 10 mg: Average 21.4% weight loss
- 5 mg: Average weight loss 16.0%
Who is it suitable for?
Current approval (EU):
- Type 2 diabetes mellitus in adults
- In combination with diet and exercise
Expected approval for obesity:
- BMI ≥ 30 or
- BMI ≥ 27 with accompanying disease
Specially promising for:
- High weight loss patients
- If other GLP-1 agonists do not work enough
- In combination of diabetes and obesity
Not suitable for:
- Type 1 diabetes
- Pancreatitis in prehistory
- Medulle thyroid cancer
- Pregnancy
Available Dosages
dosing scheme:
- Weeks 1-4: 2.5 mg weekly
- Weeks 5-8: 5 mg weekly
- Weeks 9-12: 7.5 mg weekly (optional)
- Weeks 13-16: 10 mg weekly (optional)
- From week 17: 12.5 or 15 mg weekly (optional)
Content boxes:
- 5 mg, 10 mg or 15 mg depending on the effect and compatibility
- Maximum dose: 15 mg once a week
** The dose is individually adjusted. Not everyone needs the maximum dose.
How to Take
Application:
- One week, the same weekday
- Subcutaneous injection
- belly, thigh or upper arm
- Independent meals
Pre-filled pen:
- One-time pens per dose
- Easy handling
- Needle already integrated
Change weekday: Possible if at least 3 days have passed since the last injection.
Restoration:
- In the refrigerator (2-8°C)
- Can be stored once for 21 days at room temperature
Contraindications
Contraindications:
- hypersensitivity to Tirzepatid
- Medulläres thyroid carcinoma (or family history)
- MEN 2 (Multiple endocrine neoplasia type 2)
- Heavy gastrointestinal diseases
Preview at:
- Pancreatitis in prehistory
- Diabetic retinopathy
- Gallensteinleiden
- Heavy kidney or liver failure
pregnant:
- Cancel at least 2 months before planned pregnancy
Possible Side Effects
Very common (>10%):
- nausea
- diarrhea
- Blocking
- Break.
- stomach pain
- Reduced appetite
Acid (1-10%):
- Sodburning
- Blowing
- Repulse
- fatigue
- Hypoglycemia (in diabetics)
- Reactions at the injection site
Occasionally:
- gallstones
- Increased heart rate
- Hair loss
Selten, but seriously:
- Pancreatitis
- Heavy allergic reactions
- Deterioration of diabetic retinopathy
** GI side effects are common at the beginning, but usually improve. Slow dosing helps.
Interactions
Insulin and sulfonylureas:
- Increased hypoglycemia risk
- Dose reduction of these medications necessary
Oral contraceptives:
- Reduced recording possible
- Additional prevention in GI complaints
Oral medicines in general:
- Delayed intake due to slower gastric emptying
Frequently Asked Questions
Similar Medications
Is Mounjaro right for you?
A licensed doctor will review your information and issue a prescription if suitable. Discreet and secure.
Important Notice
This information does not replace medical advice. If you have questions about your health or the suitability of this medication, please consult a doctor. Read the package leaflet before use.